Open access peer-reviewed chapter

Erlotinib in Glioblastoma – A Current Clinical Perspective

By Georg Karpel-Massler and Marc-Eric Halatsch

Submitted: September 13th 2013Reviewed: January 28th 2014Published: June 11th 2014

DOI: 10.5772/58296

Downloaded: 884

© 2014 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Georg Karpel-Massler and Marc-Eric Halatsch (June 11th 2014). Erlotinib in Glioblastoma – A Current Clinical Perspective, Tumors of the Central Nervous System Lee Roy Morgan, IntechOpen, DOI: 10.5772/58296. Available from:

Embed this chapter on your site Copy to clipboard

<iframe src="" />

Embed this code snippet in the HTML of your website to show this chapter

chapter statistics

884total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Comparative Preclinical Pharmacology and Toxicology for 4- demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOCPEN) — A Potential Neuro-Alkylating Agent for Glioblastoma (GBM) and Metastatic Cancers Involving the Central Nervous System

By Lee Roy Morgan, Andrew H. Rodgers, Gerard Bastian, Edmund Benes, William S. Waud, Christopher Papagiannis, Dan Krietlow, Branko S. Jursic, Robert F. Struck, Gerald LaHoste, Melissa Thornton, Melody Luttrell, Edward Stevens and Rodger Thompson

Related Book

New Approaches to the Management of Primary and Secondary CNS Tumors

Edited by Lee Roy Morgan

First chapter

NeuroPharmacology: As Applied to Designing New Chemotherapeutic Agents

By Andrew H. Rodgers and Lee Roy Morgan

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

+3,550 Open Access Books

+57,400 Citations in Web of Science

+108,500 IntechOpen Authors and Academic Editors

+560,000 Unique visitors per month

More about us